(+/-)-2-(4-amino-phenyl)-propionic acid amide | 81709-39-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+/-)-2-(4-amino-phenyl)-propionic acid amide
• 英文别名: (+/-)-2-(4-Amino-phenyl)-propionsaeure-amid；2-(4-aminophenyl)propionamide；4-Aminophenyl propionamide；2-(4-aminophenyl)propanamide
• CAS: 81709-39-9
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: YVUJUJYBPUQLQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chlorosulfenylbenzoyl chloride 、 (+/-)-2-(4-amino-phenyl)-propionic acid amide 以80%的产率得到
  参考文献：
  名称：

  BORDI, FABRIZIO;CATELLANI, PIER LUIGI;MORINI, GIOVANNI;PLAZZI, PIER VINCE+, FARMACO, 44,(1989) N, C. 795-807

  摘要：

  DOI：
• 作为产物：
  描述：

  (+/-)-2-(4-nitro-phenyl)-propionic acid amide 在 一氧化钯 氢气 作用下， 以 乙醇 为溶剂， 以gave the title compound as a white solid (4.5 g), m.p. 120°-122°的产率得到(+/-)-2-(4-amino-phenyl)-propionic acid amide
  参考文献：
  名称：

  Indole-5-acetamides for treatment of migraine

  摘要：

  本发明公开了一般式（I）的化合物：##STR1## 其中，R.sub.1、R.sub.3、R.sub.4、R.sub.6和R.sub.7，可以相同也可以不同，分别代表氢原子或烷基基团；R.sub.2代表氢原子或烷基、芳基、芳基烷基、环烷基或烯基基团；或者R.sub.1和R.sub.2与它们所连接的氮原子一起形成饱和的单环5到7成员环，该环可以选择性地含有进一步的杂原子；R.sub.5代表氢原子或烷基或烯基基团；或者R.sub.4和R.sub.5一起形成芳基烷基亚胺基团；Alk代表含有两个或三个碳原子的烷基链，可以是未取代或取代的，取代基为不超过两个的C.sub.1-3烷基基团；X代表氧原子或硫原子；以及其生理上可接受的盐、溶剂化合物和生物前体。所述化合物被描述为治疗偏头痛的潜在有用药物，并可以用一种或多种药学上可接受的载体或赋形剂在常规方式下制备成药物组成物。公开了各种制备该化合物的方法，包括例如，通过将具有适当的5位腈基的吲哚与适当的含氧或硫化合物反应以在吲哚核上引入所需的酰胺或硫酰胺基团的方法。

  公开号：

  US04650810A1

文献信息

• (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them
  申请人：Allegretti Marcello

  公开号：US20090093530A1

  公开（公告）日：2009-04-09

  The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders. In particular, the compounds of the invention are useful in the treatment and control of specific CXCR2 dependent pathologies such as BOS, COPD, angiogenesis and melanoma.

  本发明涉及一种新型(2R)-2-苯基丙酰胺，其在苯基的4位上带有4-磺酰氨基取代基，以及包含它们的制药组合物，用作多形核细胞和单核细胞趋化抑制剂，并且在治疗各种ELR+CXC趋化因子介导的疾病方面非常有用。特别是，本发明的化合物在治疗和控制特定的CXCR2依赖性病理方面非常有用，如BOS、COPD、血管生成和黑色素瘤。
• [EN] USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1993000086A1

  公开（公告）日：1993-01-07

  (EN) Use of a compound of general formula (I), wherein R1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, arylC1-6alkoxy, -CO2R4, -(CH2)nCN, -(CH2)nCONR5R6, -(CH2)nSO2NR5R6, C1-6alkanolyamino(CH2)n, or C1-6alkylsulphonylamino(CH2)n; R4 represents hydrogen, C1-6alkyl or arylC1-6alkyl; R5 and R6 each independently represent hydrogen or C1-6¿alkyl, or R5 and R6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R2 and R3 each independently represent hydrogen, C¿1-6alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT1-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.(FR) Utilisation d'un composé de la formule (I) dans laquelle R1 représente hydrogène, halogène, trifluorométhyle, nitro, hydroxy, C1-6alkyle, C1-6alcoxy, arylC1-6alcoxy, -CO2R4, -(CH2)nCN, -(CH2)nCONR5R6, -(CH2)nSO2NR5R6, C1-6alcanoylamino(CH2)n, ou C1-6alkylsulphonylamino(CH2)n; R4 représente hydrogène, C1-6alkyle ou arylC1-6alkyle; R5 et R6 représentent chacun indépendamment hydrogène ou C1-6alkyle, ou R5 et R6 forment avec l'atome d'azote auquel ils sont attachés une chaîne fermée, n représente 0, 1 ou 2; et R2 et R3 représentent chacun indépendamment hydrogène, C1-6alkyle ou benzyle ou forment avec l'atome d'azote auquel ils sont attachés une chaîne fermée pyrrolidino, pipéridino ou hexahydroazépino; ou d'un sel physiologiquement acceptable de ce composé, dans la fabrication d'un médicament destiné au traitement d'états tels que la migraine où un agoniste analogue au 5-HT1 est prescrit. Des composés de la formule (I), leurs procédés de préparation et des compositions pharmaceutiques les contenant sont également décrits.

  使用通式（I）的化合物，其中R1代表氢，卤素，三氟甲基，硝基，羟基，C1-6烷基，C1-6烷氧基，芳基C1-6烷氧基，-CO2R4，-(CH2)nCN，-(CH2)nCONR5R6，-(CH2)nSO2NR5R6，C1-6酰胺基(CH2)n或C1-6烷基磺酰胺基(CH2)n; R4代表氢，C1-6烷基或芳基C1-6烷基; R5和R6各自独立地表示氢或C1-6烷基，或者R5和R6与它们所连接的氮原子一起形成一个环; n表示0，1或2; R2和R3各自独立地表示氢，C1-6烷基或苄基，或者与它们所连接的氮原子一起形成吡咯烷，哌啶或六氢噁唑环; 或其生理上可接受的盐，在制造用于治疗需要5-HT1样受体激动剂的情况的药物中，例如偏头痛。还描述了通式（I）的新化合物、制备它们的方法以及含有它们的制药组合物。
• Medicaments
  申请人：SmithKline Beecham p.l.c.

  公开号：US05637611A1

  公开（公告）日：1997-06-10

  Use of a compound of general formula (I): ##STR1## wherein: R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino (CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino (CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  使用一般式(I)的化合物：##STR1## 其中：R.sup.1代表氢，卤素，三氟甲基，硝基，羟基，C.sub.1-6烷基，C.sub.1-6烷氧基，芳基C.sub.1-6烷氧基，--CO.sub.2R.sup.4，--(CH.sub.2).sub.n CN，--(CH.sub.2).sub.n CONR.sup.5 R.sup.6，--(CH.sub.2).sub.n SO.sub.2NR.sup.5 R.sup.6，C.sub.1-6烷酰胺基(CH.sub.2).sub.n或C.sub.1-6烷基磺酰胺基(CH.sub.2).sub.n; R.sup.4代表氢，C.sub.1-6烷基或芳基C.sub.1-6烷基; R.sup.5和R.sup.6各自独立地代表氢或C.sub.1-6烷基，或R.sup.5和R.sup.6与它们连接的氮原子一起形成一个环; n代表0、1或2; R.sup.2和R.sup.3各自独立地代表氢、C.sub.1-6烷基或苄基，或者与它们连接的氮原子一起形成吡咯烷，哌啶或六氢噁唑环; 或其生理上可接受的盐，在制造治疗5-HT.sub.1样受体激动剂适用的情况下的药物中，例如偏头痛。还描述了公式(I)的新化合物、制备它们的过程和含有它们的药物组成物。
• Use of tetrahydrocarbazone derivatives as 5HT.sub.1 receptor agonists
  申请人：SmithKline Beecham P.L.C.

  公开号：US05464864A1

  公开（公告）日：1995-11-07

  ##STR1## Use of a compound of general formula (I), wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl; or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  使用通式（I）的化合物，其中R.sup.1代表氢，卤素，三氟甲基，硝基，羟基，C.sub.1-6烷基，C.sub.1-6烷氧基，芳基C.sub.1-6烷氧基，--CO.sub.2R.sup.4，--(CH.sub.2).sub.nCN，--(CH.sub.2).sub.nCONR.sup.5R.sup.6，--(CH.sub.2).sub.nSO.sub.2NR.sup.5R.sup.6，C.sub.1-6烷酰胺基(CH.sub.2).sub.n，或C.sub.1-6烷基磺酰胺基(CH.sub.2).sub.n; R.sup.4代表氢，C.sub.1-6烷基或芳基C.sub.1-6烷基; R.sup.5和R.sup.6各自独立地代表氢或C.sub.1-6烷基，或R.sup.5和R.sup.6与它们连接的氮原子一起形成一个环; n代表0、1或2; R.sup.2和R.sup.3各自独立地代表氢、C.sub.1-6烷基; 或苄基或与它们连接的氮原子一起形成吡咯烷基、哌啶基或六氢杂环庚烷环; 或其生理上可接受的盐，在制造用于治疗5-HT.sub.1-样受体激动剂适应症的药物中，例如偏头痛。还描述了通式（I）的新化合物、制备它们的过程以及含有它们的制药组合物。
• Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT.sub.1 agonist use
  申请人：Smithkline Beecham plc

  公开号：US05827871A1

  公开（公告）日：1998-10-27

  Use of a compound of general formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  使用一般式（I）的化合物：##STR1##其中R.sup.1代表氢，卤素，三氟甲基，硝基，羟基，C.sub.1-6烷基，C.sub.1-6烷氧基，芳基C.sub.1-6烷氧基，--CO.sub.2R.sup.4，--(CH.sub.2).sub.n CN，--(CH.sub.2).sub.n CONR.sup.5R.sup.6，--(CH.sub.2).sub.n SO.sub.2NR.sup.5R.sup.6，C.sub.1-6烷酰氨基(CH.sub.2).sub.n，或C.sub.1-6烷基磺酰氨基(CH.sub.2).sub.n; R.sup.4代表氢，C.sub.1-6烷基或芳基C.sub.1-6烷基; R.sup.5和R.sup.6各自独立地代表氢或C.sub.1-6烷基，或R.sup.5和R.sup.6与它们连接的氮原子一起形成环; n代表0、1或2; R.sup.2和R.sup.3各自独立地代表氢，C.sub.1-6烷基或苄基，或者与它们连接的氮原子一起形成吡咯烷，哌啶或六氢噁唑环；或其生理上可接受的盐，在制备治疗5-HT.sub.1-类似激动剂适用的状况的药物中使用，例如偏头痛。还描述了公式（I）的新化合物、制备它们的方法和含有它们的药物组成物。